Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Income from Continuing Operations (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Income from Continuing Operations for 3 consecutive years, with 7024000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 53.18% to 7024000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 41573000.0, a 8.26% increase, with the full-year FY2024 number at 43253000.0, down 46.79% from a year prior.
  • Income from Continuing Operations was 7024000.0 for Q3 2025 at Mereo BioPharma, up from 14616000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1751000.0 in Q2 2023 to a low of 15001000.0 in Q3 2024.
  • A 3-year average of 9749636.36 and a median of 9108000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 599.89% in 2024, then soared 53.18% in 2025.
  • Mereo BioPharma's Income from Continuing Operations stood at 9108000.0 in 2023, then increased by 22.64% to 7046000.0 in 2024, then grew by 0.31% to 7024000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Income from Continuing Operations are 7024000.0 (Q3 2025), 14616000.0 (Q2 2025), and 12887000.0 (Q1 2025).